Mr Madan Raj Poudel
University Clinic OWL, Bielefeld (Germany)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Extremely elevated lipoprotein (a) as an independent risk factor for peripheral arterial disease in large patient cohort
Event: ESC Congress 2020
Topic: Peripheral Artery Disease
Session: Peripheral Vascular and Cerebrovascular Disease ePosters
Extremely elevated lipoprotein (a) as an independent risk factor for coronary heart disease in large patient cohort
Event: ESC Congress 2019
Topic: Prevention
Session: Long term prognosis in coronary artery disease
Real world prospective one year monocentric follow up study investigating novel lipid lowering agents class proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab
Event: EuroPrevent 2019
Topic: Lipids
Session: Risk Factors and Prevention - Lipids
Aortic valve stenosis in patients with extremely elevated lipoprotein(a) levels
Event: ESC Congress 2018
Topic: Clinical, Other
Session: Aortic disease: clinical
First real world experience with the novel lipid-lowering drug PCSK9 inhibitor evolocumab in patients undergoing lipid apheresis: 1-year follow up
Event: EuroPrevent 2018
Topic: Lipids
Session: Moderated Poster Session II
Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab /alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis
Event: EuroPrevent 2018
Topic: Lipids
Session: Lipids
Efficacy of the PCSK9 inhibitors evolocumab/alirozumab in the reduction of LDL and Lp (a) in patients with familial hypercholesterolemia/manifest atherosclerosis in a real world setting
Event: EuroPrevent 2018
Topic: Lipids
Session: Lipids
Reduction of LDL and Lp (a) under the PCSK9 inhibitor Evolocumab/Alirozumab in patients with familial hypercholesterolemia or manifest atherosclerosis
Event: EuroPrevent 2017
Topic: Lipids
Session: Diabetes/ Lipids/Obesity/Nutrition_Part 2
ESC 365 is supported by
